Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease

Inflammatory Bowel Diseases

Volumn 14, Issue 9, 2008, Pages 1197-1204

  Burke, John P ^a,b   Ferrante, Marc ^c   Dejaegher, Karen ^c   Watson, R William G ^b   Docherty, Neil G ^b   de Hertogh, Gert ^c   Vermeire, Severine ^c   Rutgeerts, Paul ^c   D'Hoore, Andre ^c   Penninckx, Freddy ^c   Geboes, Karel ^c   van Assche, Gert ^c   O'Connell, P Ronan ^a,d  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Connective tissue growth factor; Crohn's disease; Fibrosis; Infliximab; Steroids

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA; CONNECTIVE TISSUE GROWTH FACTOR; DEXAMETHASONE; FIBRONECTIN; GLUCOCORTICOID; IMMUNOMODULATING AGENT; INFLIXIMAB; MACROPHAGE MIGRATION INHIBITION FACTOR; MESALAZINE; MESSENGER RNA; OSTEOGENIC PROTEIN 1; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DRUG RESPONSE; FEMALE; FIBROBLAST CULTURE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTESTINAL FIBROSIS; INTESTINE BIOPSY; INTESTINE RESECTION; MALE; MULTIPLE CYCLE TREATMENT; PREOPERATIVE CARE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TRANSCRIPTOMICS; UPREGULATION;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN 7; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; CROHN DISEASE; FEMALE; FIBROBLASTS; FIBRONECTINS; FIBROSIS; GENE EXPRESSION PROFILING; HUMANS; INTESTINES; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 54349125596     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20482     Document Type: Article

References (49)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
2. Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis. 2004;10:55-60.
3. Graham ME, Diegelmann RF, Elson CO, et al. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology. 1988;94:257-265.
4. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241.
5. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther. 2006;23:451-463.
6. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum. 2002;45: 771-775.
7. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006;101:1030-1038.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
9. Theiss AL, Simmons JG, Jobin C, et al. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem. 2005;280:36099-36109.
10. Di Sabatino A, Pender SL, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology. 2007;133:137-149.
11. Di Sabatino A, Ciccocioppo R, Benazzato L, et al. Infliximab down-regulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. Aliment Pharmacol Ther. 2004;19: 1019-1024.
12. Beddy D, Mulsow J, Watson RW, et al. Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease. Br J Surg. 2006;93:1290-1296.
13. Burke JP, Mulsow JJ, O'Keane C, et al. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439-448.
14. Mulsow JJ, Watson RW, Fitzpatrick JM, et al. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg. 2005;242:880-887; discussion 887-889.
15. Monteleone G, Kumberova A, Croft N, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609.
16. Rieder F, Brenmoehl J, Leeb S, et al. Wound healing and fibrosis in intestinal disease. Gut. 2007;56:130-139.
17. de Jong YP, Abadia-Molina AC, Satoskar AR, et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol. 2001; 2:1061-1066.
18. Maric I, Poljak L, Zoricic S, et al. Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats. J Cell Physiol. 2003;196:258-264.
19. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-19.
20. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
21. Beddy DJ, Watson WR, Fitzpatrick JM, et al. Critical involvement of stress-activated mitogen-activated protein kinases in the regulation of intracellular adhesion molecule-1 in serosal fibroblasts isolated from patients with Crohn's disease. J Am Coll Surg. 2004;199:234-242.
22. Brannigan AE, Watson RW, Beddy D, et al. Increased adhesion molecule expression in serosal fibroblasts isolated from patients with inflammatory bowel disease is secondary to inflammation. Ann Surg. 2002; 235:507-511.
23. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology. 1996;110:975-984.
24. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004;18:816-827.
25. Crean JK, Lappin D, Godson C, et al. Connective tissue growth factor: an attractive therapeutic target in fibrotic renal disease. Expert Opin Ther Targets. 2001;5:519-530.
26. Rodgers K, McMahon B, Mitchell D, et al. Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am J Pathol. 2005;167:683-694.
27. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003;9:964-968.
28. Monteleone G, Mann J, Monteleone I, et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem. 2004;279:3925-3932.
29. Monteleone G, Del Vecchio Blanco G, Monteleone I, et al. Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology. 2005;129:1420-1429.
30. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007;204:33-39.
31. Yamane K, Ihn H, Asano Y, et al. Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol. 2003;171:3855-3862.
32. Bitzer M, von Gersdorff G, Liang D, et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev. 2000; 14:187-197.
33. Verrecchia F, Tacheau C, Wagner EF, et al. A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/ 4-specific gene expression. J Biol Chem. 2003;278:1585-1593.
34. Ohkawara T, Nishihira J, Takeda H, et al. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology. 2002;123:256-270.
35. Murakami H, Akbar SM, Matsui H, et al. Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest. 2001;31:337-343.
36. Chow F, Ozols E, Nikolic-Paterson DJ, et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65:116-128.
37. Taylor JA, Zhu Q, Irwin BH, et al. Null mutation in macrophage migration inhibitory factor (MIF) prevents muscle cell loss and fibrosis in partial bladder outlet obstruction. Am J Physiol Renal Physiol. 2006; 291:F1343-1353.
38. Hori Y, Sato S, Yamate J, et al. Immunohistochemical study of macrophage migration inhibitory factor in rat liver fibrosis induced by thioacetamide. Eur J Histochem. 2003;47:317-324.
39. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation. 2004;109:2234-2239.
40. Magi B, Bini L, Perari MG, et al. Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis. 2002; 23:3434-3444.
41. Tanino Y, Makita H, Miyamoto K, et al. Role of macrophage migration inhibitory factor in bleomycin-induced lung injury and fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2002;283:L156-162.
42. Burger-Kentischer A, Gobel H, Kleemann R, et al. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis. 2006; 184:28-38.
43. Van Molle W, Libert C. How glucocorticoids control their own strength and the balance between pro- and anti-inflammatory mediators. Eur J Immunol. 2005;35:3396-3399.
44. Calandra T, Bernhagen J, Metz CN, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995;377:68-71.
45. D'Haens G, Baert F, Van Assche G, et al. Better outcome with potent top-down induction therapy in recent onset Crohn's disease. Gut. 2005; 54:A17.
46. Van Assche G. Intramural steroid injection and endoscopic dilation for Crohn's disease. Clin Gastroenterol Hepatol. 2007;5:1027-1028.
47. East JE, Brooker JC, Rutter MD, et al. A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn's strictures. Clin Gastroenterol Hepatol. 2007;5:1065-1069.
48. Dammeier J, Beer HD, Brauchle M, et al. Dexamethasone is a novel potent inducer of connective tissue growth factor expression. Implications for glucocorticoid therapy. J Biol Chem. 1998;273:18185-18190.
49. Okada H, Kikuta T, Inoue T, et al. Dexamethasone induces connective tissue growth factor expression in renal tubular epithelial cells in a mouse strain-specific manner. Am J Pathol. 2006;168:737-747.